for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Relief Therapeutics And Neurorx To Fast Track Designation Granted By FDA To RLF-100 For Treatment Of Respiratory Distress In COVID-19

June 24 (Reuters) - RELIEF THERAPEUTICS Holding SA:

* NEURORX AND RELIEF THERAPEUTICS ANNOUNCE FAST TRACK DESIGNATION GRANTED BY FDA TO RLF-100 (AVIPTADIL) FOR TREATMENT OF RESPIRATORY DISTRESS IN COVID-19 Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up